Product image of Nuvaring (Ethinylestradiol, Etonogestrel) supplied by GNH India

Nuvaring

Active Ingredient:
Ethinylestradiol, Etonogestrel
Origin:
EU

Nuvaring (Ethinylestradiol, Etonogestrel)

Ethinylestradiol and etonogestrel, the active ingredients in Nuvaring, are synthetic hormones presented as a vaginal contraceptive ring for vaginal use. They work together to prevent pregnancy in women of reproductive age.
GNH India supplies Nuvaring as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Organon Biosciences S.R.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nuvaring is a combined hormonal contraceptive that acts on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy.

  • Contraception: provides reliable, reversible birth control by suppressing ovulation and thickening cervical mucus.
  • Menstrual cycle regulation: helps achieve more predictable monthly bleeding patterns.
  • Reduction of menstrual discomfort: can lessen dysmenorrhea and heavy bleeding associated with the menstrual cycle.

How It Works

  • Ethinylestradiol and etonogestrel in Nuvaring bind to estrogen and progestogen receptors, respectively, inhibiting the mid‑cycle surge of luteinizing hormone and preventing follicular development. The progestogen component also induces cervical mucus changes that impede sperm penetration, while the estrogen stabilizes the endometrium, collectively preventing fertilization and implantation.

Side Effects

Common Side Effects

  • Vaginal irritation or discharge: mild irritation at the insertion site.
  • Headache: transient tension‑type headaches.
  • Nausea: occasional mild stomach upset.
  • Breast tenderness: temporary swelling or soreness.
  • Mood changes: irritability or mild mood swings.
  • Spotting between periods: light vaginal bleeding.

Serious or Rare Side Effects

  • Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
  • Stroke or myocardial infarction: rare but life‑threatening events.
  • Liver tumor: hepatic adenoma or carcinoma.
  • Severe allergic reaction: anaphylaxis, rash, or swelling.
  • Gallbladder disease: cholelithiasis or cholecystitis.
  • Hyperglycemia: elevated blood sugar in susceptible individuals.

Precautions & Warnings

Before using Nuvaring, consider the following precautions:

  • Smoking: avoid use if over 35 and a smoker due to increased clot risk.
  • Cardiovascular disease: contraindicated in women with history of heart attack, stroke, or uncontrolled hypertension.
  • Liver disorders: use with caution in hepatic impairment.
  • Cancer history: avoid if personal or family history of estrogen‑dependent tumors.
  • Medication review: discuss all current drugs with a healthcare professional.
  • Store at room temperature: keep in original packaging, protect from moisture and excessive heat.

Avoid Interactions

Nuvaring may interact with several medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

  • Rifampin, phenytoin, carbamazepine, St. John’s wort: strong CYP3A4 inducers that reduce contraceptive efficacy.
  • Other estrogen‑containing products: increase risk of thromboembolic events.
  • Certain antiretrovirals (e.g., efavirenz): may lower hormone levels.

Moderate Interactions (Monitor Closely)

  • Antifungals such as ketoconazole: may increase hormone concentrations.
  • Antibiotics (e.g., tetracycline, metronidazole): slight reduction in effectiveness, monitor for breakthrough bleeding.
  • SSRIs and SNRIs: potential for increased mood‑related side effects.
  • Herbal supplements (e.g., ginseng): may affect hormone metabolism.

Frequently Asked Questions

Nuvaring is a combined hormonal contraceptive vaginal ring that provides reversible birth control for women of reproductive age. It prevents pregnancy by suppressing ovulation, thickening cervical mucus, and stabilizing the uterine lining, offering a convenient, month‑long dosing schedule.

Ethinylestradiol, a synthetic estrogen, binds to estrogen receptors and helps regulate the menstrual cycle. In Nuvaring, it works together with etonogestrel to inhibit the luteinizing hormone surge, preventing ovulation and contributing to the contraceptive effect.

The dosing regimen for Nuvaring is determined by the prescribing healthcare professional. Typically, a single ring is inserted vaginally and left in place for three weeks, followed by a one‑week ring‑free interval, but the exact schedule should follow the prescriber's instructions.

Nuvaring is intended for use only when a woman is not pregnant. If pregnancy occurs, the ring should be removed immediately. It is not recommended for breastfeeding mothers, as hormonal exposure may affect milk production and infant exposure.

To order Nuvaring, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nuvaring offers a month‑long vaginal delivery system, eliminating daily oral dosing required by pills. This can improve adherence and provide more stable hormone levels. Compared with transdermal patches or injectables, the ring is non‑invasive, easily removable, and does not require injections or skin patches.

Nuvaring should be stored at room temperature, below 25 °C, in its original packaging. Protect the ring from moisture, direct sunlight, and extreme heat to maintain its integrity and efficacy throughout the shelf life.

Nuvaring is a flexible vaginal ring that is inserted into the upper vagina by the user or a healthcare professional. It remains in place for three weeks, after which it is removed for a one‑week ring‑free interval before a new ring is inserted.

Serious risks include venous thromboembolism, stroke, myocardial infarction, and rare liver tumors. Women with a history of clotting disorders, cardiovascular disease, smoking over age 35, or certain cancers should avoid using Nuvaring.

Nuvaring is contraindicated in women who are pregnant, have a known or suspected estrogen‑dependent tumor, have active liver disease, have uncontrolled hypertension, have a history of thromboembolic events, or are smokers over 35 years old.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ethinylestradiol, Etonogestrel

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT